AbCellera Biologics (NASDAQ:ABCL) Sees Unusually-High Trading Volume – Should You Buy?

AbCellera Biologics Inc. (NASDAQ:ABCL) shares saw unusually-strong trading volume on Thursday . Approximately 5,340,846 shares changed hands during trading, a decline of 13% from the previous session’s volume of 6,108,420 shares.The stock last traded at $10.5270 and had previously closed at $10.35.

Key Stories Impacting AbCellera Biologics

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Positive Phase 2 results for ABCL635 in menopausal symptoms represent a significant validation of AbCellera’s internal drug-development strategy and have strengthened the company’s pipeline outlook. AbCellera Phase 2 clinical data
• Positive Sentiment: Truist raised its price target on AbCellera from $12 to $30 and reiterated a “buy” rating, while other coverage cited a fair-value lift following the clinical data and a Jazz Pharmaceuticals deal. The higher targets support continued investor enthusiasm, though they remain analyst opinions rather than guaranteed outcomes. Truist price target
• Positive Sentiment: AbCellera’s $200 million financing was described as oversubscribed, indicating substantial demand from investors and providing additional capital to advance its pipeline and platform activities. AbCellera offering pricing announcement

Analyst Ratings Changes

ABCL has been the subject of a number of research reports. Stifel Nicolaus raised their target price on AbCellera Biologics from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Friday, July 17th. Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price objective on the stock in a report on Tuesday, July 7th. Truist Financial lifted their target price on AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Cantor Fitzgerald lifted their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.83.

AbCellera Biologics Price Performance

The firm has a 50 day simple moving average of $6.45 and a two-hundred day simple moving average of $4.81. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -20.09 and a beta of 1.20.

AbCellera Biologics (NASDAQ:ABCL) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%.The firm had revenue of $4.05 million for the quarter, compared to the consensus estimate of $7.85 million. On average, sell-side analysts expect that AbCellera Biologics Inc. will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of AbCellera Biologics

Several hedge funds have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of AbCellera Biologics in the fourth quarter worth about $26,938,000. Two Sigma Investments LP grew its position in shares of AbCellera Biologics by 25.9% in the 3rd quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company’s stock valued at $26,031,000 after purchasing an additional 1,064,290 shares during the period. Goldman Sachs Group Inc. increased its stake in AbCellera Biologics by 1,636.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company’s stock worth $14,858,000 after purchasing an additional 4,094,268 shares in the last quarter. BlackRock Inc. bought a new stake in AbCellera Biologics during the 2nd quarter worth approximately $29,872,000. Finally, Bank of America Corp DE raised its holdings in AbCellera Biologics by 13.9% during the 1st quarter. Bank of America Corp DE now owns 2,999,936 shares of the company’s stock worth $10,470,000 after buying an additional 367,064 shares during the period. Institutional investors and hedge funds own 61.42% of the company’s stock.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.